The preliminary median progression-free survival was 4.3 months with the 4 mg/kg dose, 8.2 months with the 6 mg/kg dose, and 5.4 months with the 8 mg/kg dose.īased on these findings, the 6 mg/kg dose of datopotamab deruxtecan was identified as the recommended dose for the registrational, randomized phase 3 TROPION-Lung01 trial (NCT04656652), which is evaluating datopotamab deruxtecan versus docetaxel in patients with previously treated advanced or metastatic NSCLC who do not harbor actionable genomic alterations. Confirmed complete or partial responses were observed in 7, 6, and 19 patients, respectively.Īdditionally, 2 patients who received the 4 mg/kg dose, 2 patients who received the 6 mg/kg dose, and 1 patient who received the 8 mg/kg dose had suspected complete or partial responses, but longer follow up is needed to confirm. The preliminary efficacy results showed that datopotamab deruxtecan elicited an overall response rate of 23% (n = 9) at a dose of 4 mg/kg (n = 40), 21% (n = 8) at 6 mg/kg (n = 39), and 25% (n = 20) at 8 mg/kg (n = 80) per blinded independent central review. We look forward to seeing you at Ambu’s Capital Markets Day 2023.The investigational antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd DS-1062) demonstrated encouraging antitumor activity and a manageable safety profile in patients with advanced or metastatic non–small cell lung cancer (NSCLC), according to updated results of the phase 1 TROPION-PanTumor01 trial that were presented during the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer (WCLC). Instead, it will take place for in-person attendees only. In addition, the product demonstration from 15:00-16:00 CET will not be livestreamed during the event. Please note that online attendees will not be able to ask questions during the Q&A sessions. The same link is available on the Investor Relations site on the company’s website prior to the event. You can follow the event online through this link. Private investors are encouraged to follow the event online.Īmbu’s Capital Markets Day 2023 will be broadcasted live. Please register your in-person attendance no later than Friday 10 March 2023.ĭue to capacity constraints, please note that institutional investors, stock analysts and financial media are given in-person attendance priority to the event. We encourage you to sign up for in-person attendance now. After the event, the recorded presentations and the presentation materials will be published on Ambu’s website, /presentations/capital-markets-days. The presentations will be held in English, and they will be recorded. The product demonstration will run from 15:00-16:00 CET and will be for in-person attendees only. Furthermore, the event will feature Q&A sessions as well as a product demonstration as the final item on the agenda.Īll presentations and Q&As are held from 10:00-15:00 CET. This includes diving into the company’s strategic focus areas, its transformation program and providing a financial update on its long-term financial aspiration. On 21 March 2023, Ambu will host its Capital Markets Day for institutional investors, analysts and financial media, from 10:00-16:00 CET, at the headquarters of Ambu A/S, BaltorpbakBallerup, Denmark.Īt the event, senior executives from Ambu and external speakers will join Chief Executive Officer, Britt Meelby Jensen, in sharing insights on the company’s new ZOOM IN strategy for delivering long-term sustainable double-digit revenue growth. Ambu invites institutional investors, analysts and financial media to the company’s Capital Markets Day on Tuesday 21 March 2023.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |